Your session is about to expire
← Back to Search
Transcutaneous Magnetic Stimulation
Transcutaneous Magnetic Stimulation for Ventricular Tachycardia
N/A
Waitlist Available
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age >18years
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed immediately following stimulation
Awards & highlights
Study Summary
This trial will test whether a new treatment, transcutaneous magnetic stimulation, can help people with a heart rhythm problem called ventricular tachycardia.
Who is the study for?
This trial is for adults over 18 who've had a rapid heartbeat condition called ventricular tachycardia in the last 72 hours. It's not for pregnant individuals, those with devices like heart pumps or brain stimulators implanted, metal in their head/neck (except dental), ocular implants, neck cancer history, or cochlear implants.Check my eligibility
What is being tested?
The study is testing TcMS (transcutaneous magnetic stimulation) targeting the stellate ganglion to treat ventricular tachycardia. It's an open-label study which means everyone knows they're getting this non-invasive treatment.See study design
What are the potential side effects?
Potential side effects of TcMS may include discomfort at the stimulation site, skin irritation, headache or dizziness during and after treatment. Since it's non-invasive and doesn't involve drugs, systemic side effects are unlikely.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am older than 18 years.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0-72 hours after enrollment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-72 hours after enrollment
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Ventricular Tachycardia
Secondary outcome measures
Discomfort
Non sustained ventricular tachycardia
Trial Design
1Treatment groups
Experimental Treatment
Group I: Transcutaneous magnetic stimulationExperimental Treatment1 Intervention
Transcutaneous magnetic stimulation targeting the stellate ganglion
Find a Location
Who is running the clinical trial?
University of PennsylvaniaLead Sponsor
2,000 Previous Clinical Trials
42,880,088 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a ventricular assist device implanted.You have experienced a specific type of heart rhythm problem called ventricular tachycardia in the past 3 days.You have a cochlear implant.You have a medication pump implanted in your body.You have a device in your brain that helps control movement.You have an implant in your eye.I have had cancer in my neck area before.I am older than 18 years.
Research Study Groups:
This trial has the following groups:- Group 1: Transcutaneous magnetic stimulation
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there vacancies available for potential participants in this experiment?
"According to clinicaltrials.gov, this study has concluded its recruitment phase and is not currently accepting applicants. The trial was first posted on the 1st of December 2022 with the last edit being made on January 14th that same year. Fortunately, there are still 124 other studies recruiting patients right now."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger